Sangeetha Sundaramoorthy has submitted to the Exchange a copy of Disclosures under Regulation 10(6)-Report to stock Exchange in respect of any acquisition made in reliance upon exemption provided for in regulation 10 of SEBI (SAST) Regulations, 2011
LOTUSEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sangeetha Sundaramoorthy, a promoter of Lotus Eye Hospital, acquired 14,28,571 shares (6.87% of diluted share capital) from fellow promoter Kavetha Sundaramoorthy at Rs. 70 per share via a Share Purchase Agreement dated June 2, 2025, with the transaction executed on February 27, 2026. The acquirer's stake rose from 28.14% (58,51,901 shares) to 35.01% (72,80,472 shares), while the seller's stake fell from 9.61% (19,99,564 shares) to 2.75% (5,70,993 shares). The transfer qualifies for an exemption from making an open offer under Regulation 10(1)(a)(i), which covers inter-se transfers among promoters. The combined promoter shareholding remains broadly unchanged at around 37.76%, as this is a reshuffle within the promoter group rather than a change in overall promoter control.
No change in total promoter ownership or control of the company — the stock price is unlikely to be materially affected since the shares merely shifted between two promoters. Shareholders should note that the acquirer's individual holding crossed 35%, though it remains well below any open-offer trigger threshold.